Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes

• Åsa Ericsson ,

  Contributed equally to this work with: Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen, Adam Fridhammar

  Roles Writing – original draft, Writing – review & editing

  * E-mail: ASAE@novonordisk.com

  Affiliation Diabetes Marketing, Novo Nordisk Scandinavia AB, Malmö, Sweden

  http://orcid.org/0000-0002-3226-7469

  ⨯
• Divina Glah ,

  Contributed equally to this work with: Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen, Adam Fridhammar

  Roles Writing – original draft, Writing – review & editing

  Affiliation Formerly: Health Economics & Outcomes Research, Novo Nordisk Ltd, Gatwick, United Kingdom

  ⨯
• Maria Lorenzi ,

  Contributed equally to this work with: Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen, Adam Fridhammar

  Roles Writing – original draft, Writing – review & editing

  Affiliation Evidence Synthesis and Decision Modelling, Precision Health Economics, San Francisco, CA, United States of America

  ⨯
• Jeroen P. Jansen ,

  Contributed equally to this work with: Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen, Adam Fridhammar

  Roles Writing – original draft, Writing – review & editing

  Affiliation Evidence Synthesis and Decision Modelling, Precision Health Economics, San Francisco, CA, United States of America

  ⨯
• Adam Fridhammar

  Contributed equally to this work with: Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen, Adam Fridhammar

  Roles Writing – original draft, Writing – review & editing

  Affiliation Research Manager, The Swedish Institute for Health Economics, Lund, Sweden

  ⨯